Insights Into Direct Oral Anticoagulant Therapy Implementation of Stroke Survivors with Atrial Fibrillation in an Ambulatory Setting
Valerie Albert, Alexandros A Polymeris, Fine Dietrich, Stefan T Engelter, Kurt E Hersberger, Sabine Schaedelin, Philippe A Lyrer, Isabelle Arnet, Valerie Albert, Alexandros A Polymeris, Fine Dietrich, Stefan T Engelter, Kurt E Hersberger, Sabine Schaedelin, Philippe A Lyrer, Isabelle Arnet
Abstract
Objectives: To describe how stroke survivors with atrial fibrillation implement direct oral anticoagulant treatment and propose appropriate metrics to describe adherence.
Materials and methods: Stroke patients with atrial fibrillation electronically recorded their self-administered direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban) during a 6-month observation phase after hospitalisation for ischemic stroke. Taking and timing adherence, correct dosing days, drug holidays, time of the day and day of the week subsets, dose-to-dose intervals and longest intervals between two consecutive doses were calculated from electronic monitoring data to describe and discuss the implementation phase of adherence.
Results: Data from 41 patients were analysed. Median age was 77 (IQR = 69-84), 63.4% were male and the majority suffered a mild stroke (median NIHSS: 1). Mean taking and timing adherence exceeded 90%. Correct dosing occurred in 86.6% of the days. Seven patients (17.1%) had intake pauses of three or more consecutive days. Patients with twice-daily regimen (70.7%) had higher taking adherence in the morning than in the evening (94.4% versus 89.9%; p = 0.001). No therapy- or anamneses-related characteristic was associated with taking adherence.
Conclusions: Although adherence to direct oral anticoagulants of stroke patients with atrial fibrillation exceeded 90%, deviant intake patterns such as drug holidays and missed evening doses were common and raise concerns. Appropriate adherence metrics calculated from electronic monitoring data may guide healthcare professionals elucidating patient-tailored adherence-enhancing interventions. ClinicalTrials.gov registration number: NCT03344146.
Keywords: Atrial fibrillation; Direct oral anticoagulants; Electronic monitoring; Ischemic stroke; Medication adherence.
Conflict of interest statement
Declaration of Competing Interest We report no conflict of interest
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Source: PubMed